en · de · es
cjc-1295-notes.peptides6579.com › Topic › Receptor Action And Clearance — Practical Notes

Receptor Action And Clearance — Practical Notes

By Editorial Desk · published 2026-07-12 · last reviewed 2026-07-31 · Topic

Everything below concerns GHRH receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-07-31. Numbers and descriptions here follow the published literature rather than marketing material.

Receptor Action and Clearance

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.

Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.

Mechanism and Pharmacokinetics

Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.

Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.

Cjc-1295 at a glance

PropertyValueNotes
Primary targetGHRH receptorPresent on pituitary somatotroph cells
Signal pathwayGs, cyclic AMP, protein kinase ASequence follows receptor activation
Main measured effectGrowth hormone releaseInsulin-like growth factor 1 shifts indirectly
Half-life, binding formSeveral daysExtended through serum albumin association
Half-life, unmodified formAbout 30 minutesLimited mainly by enzymatic cleavage

Background and Molecular Design

Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.

The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.

Related pages on this site

Molecular Background and Naming

CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.

Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.

Supporting material

At 7pm on January 9, Urquía Carreño called Viñas Alonso and asked if they could meet in private. Urquía Carreño brought Airán Cervera with him, and they met in Viñas Alonso's home. Urquía Carreño and Airán Cervera then informed him about the missing safe. Viñas Alonso said: "This is a very serious situation.... Did you call the police?" Urquía Carreño replied that he had not, to avoid damaging Freemasonry's image. Viñas Alonso asked why Urquía Carreño waited four days to inform him that the safe was missing, but Airán Cervera assured him that they could have the money replaced by March. "We talk all the time. You should have told me. You should have gone to the police... Just leave. I need time to think. This is all very serious." Viñas Alonso said. Urquía Carreño and Airán Cervera left. At 9pm on January 9, Viñas Alonso deliberated scheduling an urgent meeting of the Board of Trustees for the next day. He called Urquía Carreño to discuss this option. "Don't do that, it won't benefit anyone," Urquía Carreño said. Viñas Alonso then insisted the meeting would take place at 4pm. At the emergency meeting of the Board of Trustees on January 9, the Board of Trustees was made aware of the situation, and Viñas Alonso made a motion for a vote on two proposals. The first was to go immediately to the National Revolutionary Police and file a police report. The second proposal was to draft a report that would be sent out to all Cuban Freemasons detailing the events which took place.

Anti-aging creams are predominantly moisturizer-based skin care products marketed with unproven claims of making the consumer look younger by reducing, masking or preventing signs of skin aging such as wrinkles. In the United States, anti-aging products are commonly marketed with false health claims, and are deemed to be among various scams on consumers.

Tim Hortons, currently owned by Restaurant Brands International, opened its first store on May 17, 1964, in Hamilton, Ontario. It is the fourth largest publicly traded quick-service restaurant chain in North America based on market capitalization, and the largest in Canada. It has cornered the Canadian market for baked goods (76%) and coffee (62% compared to Starbucks, in the number two position, at 7%). The company has experienced substantial growth in the United States, where it has 613 stores (April 2011, about 220 more than it had in June 2008). It has a same-store sales growth rate of 3.9% in Canada and 4.9% in the US. The new partnership with Cold Stone Creamery helped push its US presence to over 600 stores. The partnership has since dissolved. Sales exceeded $2 billion in 2008. It was controlled by Wendy's International Inc. for 11 of the 46 years of operation, from August 8, 1995, until the end of 2006. On April 3, 2011, Tim Hortons oversaw 3,782 locations in North America 3,169 of which were in Canada. In the fourth quarter of 2010 Tim Hortons' profits were 27% more than they were over the entire 2009 fiscal year (for the quarter net income was up 314%). In Forbes' 2011 edition of the world's 2000 largest companies, Tim Hortons placed 1469th overall (up from 1714th in 2010) with annual sales of $2.6 billion (up from $2.014 billion in 2010), profits totalling $628 million (up from $280 million), assets worth $2.5 billion (up from $1.90 billion) and a market value of $7.5 billion (up from $5.41 billion).

Chetumal province, which encompassed the area around Corozal Bay Dzuluinicob province, which encompassed the area between the lower New River and the Sibun River, west to Tipu a southern territory controlled by the Manche Ch'ol Maya, encompassing the area between the Monkey River and the Sarstoon River.

There are various techniques used in manual therapy for patients with CTS. Some examples include manual and instrumental soft tissue mobilizations, massage therapy, bone mobilizations or manipulations, and neurodynamic techniques, focused on the skeletal system or soft tissue. In cases of epineural tethering in the upper extremity, manual therapy can reduce this dysfunction. It can have a positive impact on the gliding of the nerves through the carpal tunnel while moving the elbow, fingers, or wrist. Manual therapy included the incorporation of specified neurodynamic techniques, functional massage, and carpal bone mobilizations. People who receive physical therapy report less pain and an increased functional ability of their wrists and hands. Self-myofascial ligament stretching has been suggested as an effective technique, although a meta-analysis claimed this form of therapy does not show significant improvement in symptoms or function. However, stretching with a physical therapist can be more beneficial than if the patient stretches alone. Tendon and nerve gliding exercises appear to be useful in carpal tunnel syndrome.

Sources: en.wikipedia.org

Supporting material

=== Software === SIP (software), a tool which generates C++ interface code for the programming language Python Scilab Image Processing, an image processing toolbox Soft Input Panel, on-screen input method for devices without standard keyboards Submission Information Packages, in the Open Archival Information System Reference Model; see Open Archival Information System#The OAIS environment and information model System Integrity Protection, a security feature of macOS by Apple, starting with OS X El Capitan

=== Regulation === PCP is a Schedule II substance in the US. The Administrative Controlled Substances Code Number (ACSCN) for PCP is 7471. Its manufacturing quota for 2014 was 19 grams (0.67 oz). It is a Schedule I drug by the Controlled Drugs and Substances act in Canada, a List I drug of the Opium Law in the Netherlands, and a Class A substance in the UK.

=== Blood tests === Among the most common effects of this drug is increased blood cholesterol levels. Other changes in blood chemistry such as hypomagnesemia, hypocalcemia, hyperkalemia, and an increase in blood urea nitrogen (BUN) can occur.

Sulfur dioxygenase (EC 1.13.11.18, sulfur oxygenase, sulfur:oxygen oxidoreductase) is an enzyme with systematic name S-sulfanylglutathione:oxygen oxidoreductase. This enzyme catalyses the following chemical reaction

Sources: en.wikipedia.org

Frequently asked questions

Which receptor does the compound target?

It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.

How does the albumin-binding group alter behavior?

It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.

What do studies generally measure?

Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.

How long does the albumin-binding form remain active?

Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.

Network